Hematologic Oncology Treatment Center

Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.

Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.

Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.

Dr. Corey Cutler presented evidence demonstrating that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS).

Dr. Caron Jacobson presented the primary analysis of Zuma-5, a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma.

Dr. Jacqueline Garcia presented results of a trial using venetoclax in stem cell transplants regimens for patients with high-risk myeloid cancers.

Dr. Mark Bustoros presented data from a phase 2 clinical trial of three oral drugs showing high response rate with tolerable effects in high risk smoldering multiple myeloma.

Dr. Reid Merryman presented a new analysis showing that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.